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Abstract Previously we have reported expression of an mRNA
with homology to the Na+-dependent glutamate transporter,
GLAST-1, in bone. Here we demonstrate that the complete open
reading frame of GLAST-1 mRNA and corresponding 69 kDa
protein are expressed in rat bone in vivo. We have also discovered
a novel splice variant (GLAST-1a), lacking exon 3, expressed in
rat bone and brain. A 55 kDa protein detected by anti-GLAST
antibody in rat cerebellum corresponds to the molecular weight
of unglycosylated GLAST-1a. This has led us to propose that
GLAST-1a has an opposite orientation in the cell membrane to
GLAST-1. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Maintenance of optimal bone mass is controlled by sys-
temic hormones and local factors such as cytokines, growth
factors and the mechanical environment of bone cells. An
imbalance of these factors may disrupt bone turnover and
result in pathological bone loss. Glutamate signalling, more
commonly associated with the central nervous system (CNS),
has recently been implicated as a mechanism by which bone
cells might communicate in response to their mechanical en-
vironment. This was ¢rst suggested by the discovery that an
mRNA with homology to GLAST-1 is down-regulated by
mechanical loading of osteocytes in vivo [1].
In the CNS, GLAST-1 functions as a Na-dependent sym-
port of glutamate and aspartate that transports free excitatory
amino acids (EAA) subsequent to neurotransmission [2]. The
family of neurotransmitters to which GLAST-1 belongs also
act as ligand-gated chloride channels that can regulate excita-
tory neurotransmission [3]. The protein structure of the high
a⁄nity Na-dependent EAA transporters has been studied
extensively (reviewed by Slotboom et al. [4]). While it is
agreed that GLAST-1 has six transmembrane (TM) K-helices
at the N-terminal end, the C-terminal structure is less clear.
Wahle and Sto¡el proposed that the C-terminal is composed
of four TM L-sheets [5] but Seal et al. propose a TM K-helix
N-terminal of a re-entrant loop pore, followed by two hydro-
phobic regions that do not span the membrane and a ¢nal
TM K-helix [2]. Further evidence for the re-entrant loop hy-
pothesis is also provided by cysteine scanning mutagenesis
studies in homologous regions of other members of the glu-
tamate transporter family: rat Glt-1 [6] and GltT expressed by
Bacillus stearothermophilus [7].
Our previous study suggested that GLAST-1 is expressed as
a number of splice variants. Firstly, the di¡erential display
clone isolated as a mechanically regulated gene in osteocytes
showed 81% identity with the 3P untranslated region (UTR) of
GLAST-1 over 33 bases, although spanning sequences were
not similar. Secondly, Northern blot analysis using a probe to
a translated region of GLAST-1 (bases 310^655, accession no.
S49018) revealed expression of 2.6 kb and 4.5 kb mRNAs in
brain and a single 2.6 kb transcript in bone [1].
Here we have used reverse transcription (RT)-PCR to show
all 10 exons of GLAST-1 are expressed in bone in vivo. Se-
quencing of cloned RT-PCR products revealed the expression
of two mRNA transcripts, one containing the complete open
reading frame (ORF) (GLAST-1) and a novel variant where
exon 3 is deleted (GLAST-1a). Western blot analysis revealed
immunoreactive protein species corresponding to the molecu-
lar weight of both GLAST-1 and GLAST-1a. Recent data
showing that glutamate uptake by astrocytes is mediated by
increased transporter activity rather than receptor activation
[8] suggest that transporters such as GLAST may control
EAA signalling. If GLAST-1a represents a functional trans-
porter, it is critical that it is considered when unraveling
mechanisms of glutamate signalling both in brain and bone.
2. Materials and methods
2.1. Tissue preparation and RNA extraction
Rat tibiae were dissected from Wistar rats and epiphyses removed.
Diaphyses were placed into 1.5 ml centrifuge tubes and the bone
marrow £ushed from the cavity by centrifugation at 1000 rpm for
30 s. Bones were snap frozen in liquid nitrogen and powdered
(B. Braun Biotech Dismembrator, 2000 rpm for 3 min at 3120‡C)
in 1 ml Trizol0 reagent (Gibco, BRL). Total RNA was extracted
following the manufacturer’s instructions, precipitated with 0.5%
(v/v) isopropanol and puri¢ed with 0.05% (v/v) Tack resin (Biogene-
sis). RNA was extracted from 100 mg of rat cerebellum using the
same method. Contaminating genomic DNA was removed from all
RNA samples by digestion with 2 U of RQ1 DNase (Promega) in the
presence of 40 U RNasin0 ribonuclease inhibitor (Promega) at 37‡C
for 15 min. DNase was removed by re-extraction of RNA in 500 Wl
Trizol0, and concentration and purity of RNA were estimated by
measuring absorbance at 260 nm and 280 nm.
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2.2. RT-PCR of GLAST mRNA
2.5 Wg of RNA, primed with 0.5 Wg of Oligo dT15, was reverse-
transcribed using Superscript1 II (Gibco, BRL) according to the
manufacturer’s instructions. cDNA samples were made up to 100 Wl
with dH2O. PCR primers designed to sequences in exon 1 (forward
5P-TCCACCAGTCACAGAATCAGA) and exon 10 (reverse 5P-GA-
GTCAGAAGAAAGGGCAAAC) of the published GLAST-1 se-
quence (accession no. S49018 [9]) were used to amplify bases 66^
2267 of the GLAST-1 cDNA. 1 Wl of bone cDNA was ampli¢ed in
25 Wl (3 mM MgCl2, 150 nM of each primer, 1 U of Advantage DNA
polymerase in 1U reaction bu¡er (Clontech)). Thermocycling param-
eters were 40 cycles of 95‡C for 1 min, 63‡C for 1 min and 72‡C for
2.5 min. Amplicons were incubated at 95‡C for 20 min to inactivate
proofreading enzyme.
2.3. Cloning of GLAST cDNAs
Adenosine overhangs were added to the 3P ends of the GLAST-1
RT-PCR products by a further 20 min incubation at 72‡C in the
presence of 5 U of Taq polymerase (AGS gold: Hybaid). Amplicons
were TA-cloned into pCR0-XL-TOPO and transformed into TOPO
10 chemically competent cells following the manufacturer’s instruc-
tions (Invitrogen). Plasmids were puri¢ed (Wizard0 SV Plus miniprep
kit, Promega) and 5 Wl restricted with 5 U of EcoRI (37‡C, 1 h, 1U
bu¡er containing 10 Wg bovine serum albumin (Promega)) to con¢rm
the presence of the insert. Clones were sequenced using M13 vector
primers and forward and reverse sequencing primers designed to
GLAST-1 (forward: 762 5P-CCAGCTATGAGAAGAGAAGCTT
and reverse: 1630 5P-GTGGTTCGGAGGCGGTCCAG accession
no. S49018).
2.4. Con¢rmation of expression of GLAST-1a splice variant in bone
and brain
Primers were designed to speci¢cally amplify the GLAST-1a splice
variant. The forward primer (5P-CAGCGCTGTCATTGTGG-
GAATGGC) was designed to prime across the exon 2^4 boundary
and the reverse primer (5P-AGGAAGGCATCTGCGGCAGTCACC)
was designed to the 3P end of exon 4 of GLAST-1 (bases 285^495,
accession no. AF265360). 1 Wl of bone cDNA was ampli¢ed in a 25 Wl
reaction (3 mM MgCl2, 150 nM of each primer, 1 U of AGS DNA
polymerase in 1U reaction bu¡er (Hybaid)). Thermocycling parame-
ters were 40 cycles of 95‡C for 1 min, 58‡C for 1 min and 72‡C for
2 min.
Fig. 1. (A) EcoRI digest of cloned products from exon 1^10 PCR revealed two di¡erent sized inserts. (B) BLAST2 comparison (www.ncbi.nlm.
nih.gov/gorf/b12.html) of the inserts derived from exon 1^10 PCR of bone cDNA. Bases 241^540 of GLAST-1 (G-1) and 241^402 of GLAST-
1a (G-1a) illustrate the absence of exon 3 in GLAST-1a. Flanking sequences were identical. (C) RT-PCR using GLAST-1a speci¢c primers re-
vealed the expected 210 bp product in rat tibia (1) and brain (2), lane 3 = water control.
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2.5. Analysis of hydrophobicity
Hydrophobicity plots were performed on amino acids 1^172 of
GLAST-1 and 1^126 of GLAST-1a using TMPRED (www.embnet.
org/software/TMPRED_form.html).
2.6. Protein extraction
Rat long bone and cerebellum samples were homogenised using a
dismembrator (B. Braun Biotech) for 3 min at 2000 rpm at 3120‡C in
1 ml 10 mM Tris^HCl (pH 7.5), 1 Wg/ml soya bean trypsin inhibitor,
1.2 mg/ml N-ethylmaleimide, 10 Wg/ml pepstatin, 1 mM phenylmeth-
ylsulfonyl £uoride, 1 mM ethylenediaminotetraacetic acid and 2 mM
dithiothreitol (DTT). The tissue homogenates were fractionated se-
quentially by centrifugation at 10 000Ug for 1 h at 4‡C (pellet taken
as crude extract) and 100 000Ug at 4‡C for 1 h (pellet taken as
membrane-enriched extract). Pellets were resuspended in 100 Wl
10 mM Tris^HCl (pH 7.5), 2 mM DTT and incubated at room tem-
perature for 1 h. Both fractions were alkylated by incubating for
15 min with 5 mM iodoacetamide at room temperature. Fractions
were freeze-dried overnight.
2.7. Western blot analysis using anti-GLAST-1 antibody
Immunoblot analysis [10] was used to con¢rm the presence of
GLAST-1 protein expression in long bones and to identify GLAST
isoforms present in rat cerebellum. Lyophilised fractions were dis-
solved in sample bu¡er (8 M urea, 2 M thiourea, 5% (w/v) sodium
dodecyl sulfate (SDS), 25 mM Tris^HCl (pH 7.5), 1% (w/v) bromo-
phenol blue and 5% (v/v) L-mercaptoethanol) to a ¢nal concentration
of 10 mg/ml and incubated at 60‡C for 15 min. 50 Wg of each extract
was resolved on 7.5% or 10% SDS^polyacrylamide gels and subse-
quently transferred to polyvinyldi£uoride membrane (Immobilon-
PVDF, Millipore). 5 Wl of prestained SDS^PAGE protein standards
(Bio-Rad Laboratories) was also resolved on each gel and the mobil-
ities of these standards (molecular weights 28.5^113 kDa) were used
to determine the molecular weight of GLAST isoforms.
Non-speci¢c binding sites on the membrane were blocked by incu-
bating in 1% (w/v) skimmed milk powder in TBS (0.05 M Tris^HCl,
pH 8.0, 0.15 M NaCl) for 30 min. Membranes were incubated sequen-
tially with an antibody preparation that recognises amino acids 24^40
of the rat GLAST-1 protein (kindly provided by Wilhelm Sto¡el,
University of Cologne [5]), diluted 1:1000 in TBS containing 0.2%
(v/v) Tween 20 (TBS-Tween) and horseradish peroxidase-conjugated
anti-rabbit IgG diluted 1:10 000 with TBS-Tween. An additional blot
was incubated without primary antibody to control for non-speci¢c
binding of secondary antibody. Membranes were washed extensively
in between incubations with TBS-Tween. Speci¢c binding of the anti-
GLAST-1 antibody was detected by enhanced chemiluminescence on
Hyper¢lm-ECL (Amersham, UK).
3. Results
3.1. GLAST-1 cDNA from bone
RT-PCR of bone RNA using primers to exons 1 and 10 of
the published GLAST-1 sequence [9] yielded an amplicon of
the expected 2201 bp for this molecule. Sequence analysis
con¢rmed that this bone-derived PCR product contained the
complete ORF of GLAST-1 mRNA previously thought to be
exclusively expressed in the CNS of both rats and humans [9].
The bone cDNA sequence di¡ers from the published GLAST-
1 sequence [9] by a G to C transversion resulting in a valine to
leucine polymorphism at amino acid number 302 as observed
in more recent brain-derived GLAST-1 cDNA by other work-
ers [11].
3.2. A splice variant that excises exon 3
EcoRI restriction digest of cloned exon 1^10 PCR products
yielded an insert of approximately 2 kb as well as the expected
2.2 kb (Fig. 1A). Comparison of DNA sequence data revealed
a novel variant of GLAST-1 mRNA that does not possess
exon 3 (Fig. 1B). We have called this variant GLAST-1a
and it has been assigned DDBJ/EMBL/GenBank accession
number AF265360. RT-PCR, using an upstream primer to
the exon 2^4 boundary and a downstream primer to exon 4
to speci¢cally amplify GLAST-1a, demonstrated that it is ex-
pressed in brain as well as bone in vivo (Fig. 1C).
3.3. TM modelling
Hydrophobicity predictions of the ¢rst four exons of
GLAST-1 reveal that they encode three hydrophobic regions
that correspond to potential TM domains (Fig. 2A). Interest-
ingly TM prediction of the hypothetical protein without exon
3 reveals that there are only two hydrophobic regions, which
would correspond to just two TM domains (Fig. 2B). Thus
loss of exon 3 alters the N-terminal region from the three
potential TM domains of GLAST-1 to two in GLAST-1a.
3.4. GLAST proteins are expressed in bone and brain
Western blot analysis revealed a number of proteins ex-
pressed in bone and brain with reactivity to the anti-GLAST
antibody (Fig. 3). Molecular weights þ S.D. are given from
Fig. 2. Hydrophobicity plots of the amino acids (A) 1^172 of GLAST-1, (B) 1^126 of GLAST-1a (TM prediction: www.ch.embnet.org/soft-
ware/TMPRED_form.html). Showing three TM domains in GLAST-1 and two in GLAST-1a.
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three independent determinations. Both brain and bone ex-
press a 69 þ 0.1 kDa protein and a 64 þ 5.4 kDa protein was
also observed in brain. The molecular weights of these pro-
teins suggest they correspond to the two glycosylation states
of the GLAST-1 glycoprotein reported by Condradt et al.
[12]. Three larger proteins (114 þ 2.4 kDa and 89 þ 3.0 kDa
in brain; 111 kDa in bone) probably represent multimers of
GLAST that have been described previously [13]. We also
detect 55 þ 3.0 kDa and 48 þ 3.0 kDa immunoreactive proteins
in the brain membrane-enriched fraction that have not been
described previously. The 55 kDa protein corresponds closely
to the calculated molecular weight of unglycosylated GLAST-
1a (54.4 kDa).
4. Discussion
The role of GLAST-1, a Na-dependent transporter of
EAAs, has been extensively studied in the rat CNS.
GLAST-1 is a member of the family of high a⁄nity glutamate
transporters responsible for terminating the excitatory signal
across the nerve synapse.
Previously, we identi¢ed a molecule with homology to bases
2574^2606 of the 3P UTR of GLAST-1 as a candidate gene
for involvement in osteogenesis in vivo [1]. RT-PCR con-
¢rmed that an mRNA possessing exons 2, 3 and 4 of
GLAST-1 is expressed in rat bone, suggesting a potential
role for EAAs in bone cell signalling. In support of this, other
components of the glutamate signalling system have since
been identi¢ed in bone and bone cell lines. The metabotropic
glutamate receptor mGluR1b mRNA has been detected in rat
primary osteoblasts [14] and the ionotropic N-methyl-D-as-
partic acid receptor (NMDAR) subunits 1, 2 and 3 are present
in clonal (MG-63, SaOS-2) and primary osteoblasts [15,16].
NMDAR 1 protein is expressed by osteoclasts and osteoblasts
in vivo [15,17]. The glutamate vesicle-associated protein
(Doc2) and synaptic proteins (syntaxin 1,4,6, SNAP-25,
rSec8, synaptophysin) have been shown to colocalise with
glutamate in clonal (MG-63, SaOS-2, TE85) and primary
rat osteoblasts [18]. These data reveal that the molecular ma-
chinery for glutamate signalling is present in osteoblasts and
electrophysiological analysis suggests bone cells have func-
tional NMDAR [19] and mGluR activity [14]. The restriction
of EAA signalling to the CNS has been questioned by reports
of GLAST-1 mRNA expression in other tissues [11] and there
is now good evidence for this signalling mechanism in
bone.
4.1. The complete ORF of GLAST-1 is expressed in bone
We have used RT-PCR to demonstrate that an mRNA
molecule that possesses exons 1^10 of GLAST-1 is expressed
in rat bone. This ¢rst report of the expression of the entire
ORF of GLAST-1 in bone suggests that functional GLAST-1
protein is expressed in this tissue. The di¡erential display
clone originally isolated as a mechanically regulated gene in
osteocytes represented the 220 bp of cDNA adjacent to the
poly A tail. 33 bases of this clone showed 81% identity with
the 3P UTR of GLAST-1 but £anking sequences were not
similar [1]. The sequence described in this paper includes
416 bases of the 5P end of the 3P UTR which is identical in
bone-derived GLAST-1, GLAST-1a and the published brain-
derived cDNA sequence (accession no. S49018). Since North-
ern blot analysis using a probe to a translated region of
GLAST-1 (bases 310^655, accession no. S49018) revealed
2.6 and 4.5 kb mRNAs in brain and a single 2.6 kb transcript
in bone [1], we predict that further splicing in the UTR may
occur. The 3P UTR of GLAST-1 has a number of potential
splice sites (Huggett and Mason, unpublished data) which
may alternatively splice the GLAST-1 and/or GLAST-1a
transcripts in bone explaining the di¡erences in size observed
by Northern blot analysis.
Fig. 4. Topological model of (A) GLAST-1 [2] and our hypothetical model of (B) GLAST-1a. The loss of exon 3 transforms the ¢rst two TM
domains into one, which we predict will £ip the C-terminal and reverse glutamate (E) transport. Note extracellular asparagine residues N206
and N216 become intracellular in GLAST-1a.
Fig. 3. Western blot analysis using anti-GLAST antibody. Lanes 1
and 2 = cerebellum crude and membrane-enriched fractions, respec-
tively. Lanes 3 and 4 = bone crude and membrane-enriched frac-
tions, respectively. Band sizes shown in kDa þ S.D. derived from
three independent determinations. Bands marked with * are due to
non-speci¢c binding of secondary antibody.
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4.2. A novel splice variant of the GLAST gene
We detected the expression of a novel variant of GLAST-1
with exon 3 excised in rat bone and brain. Exon 3 is in frame
at phase 1 in rats and humans. Splicing of exons 2 and 4
generates a novel but conservative codon (GGA) to that at
the exon 2 to 3 boundary (GGT) which both encode a glycine
residue. The loss of the 46 amino acid residues encoded by
exon 3 would considerably alter the structure of the protein
that might be translated from this transcript. Previous predic-
tions of GLAST-1 protein structure agree that there are six
TM K-helices in the N-terminal [2,5,20]. There is some dis-
agreement as to the structure of the remaining C-terminal ;
Seal et al. predict that this region has a re-entrant loop [2]
(Fig. 4A) while Wahle et al. favour the formation of four L-
sheets [5]. The ¢rst three TM K-helices (amino acids 48^68,
91^111 and 121^145) are encoded by exons 2, 3 and 4 in
GLAST-1 (Fig. 2A), however, the loss of exon 3 in
GLAST-1a removes amino acids 61^107 (Fig. 2B). Conse-
quently GLAST-1a protein will lose the ¢rst extracellular do-
main and a portion of the ¢rst and second TM domains of
GLAST-1 such that the ¢rst and second hydrophobic regions
fuse to generate a single predicted TM domain (Fig. 4B).
Hydrophobicity analysis indicates that if GLAST-1a en-
codes a functional transporter, its orientation within the plas-
ma membrane may be reversed resulting in an extracellular C-
terminal and intracellular localisation of N-glycosylation sites
206 and 216 [12].
4.3. Expression of GLAST proteins in bone and brain
The detection of a V69 kDa protein with an anti-GLAST
antibody (Fig. 3) within the bone and brain samples reveals
that bone is expressing the GLAST-1 protein described by
Storck et al. [9]. Since the predicted molecular weight of un-
glycosylated GLAST-1a is 54.4 kDa, the detection of a V55
kDa protein in brain (Fig. 3) supports the notion that
GLAST-1a is also expressed at the protein level. If GLAST-
1a was glycosylated in the same manner as GLAST-1, then a
much larger protein molecular weight would be expected;
unglycosylated GLAST-1 has a molecular weight of 59.6
kDa, however the glycoprotein has been detected as isomers
of 64 kDa and 70 kDa [12].
4.4. Potential assembly of GLAST-1a
The assembly of TM proteins in eukaryotes is not fully
understood, the most simple model is sequential start stop
transfer where hydrophobic domains insert into the plasma
membrane one after the other in an orientation governed by
the most N-terminal sequence [21]. This model was questioned
as the only mechanism of membrane protein assembly by
Gafvelin et al. who demonstrated that the presence or absence
of positively charged residues in the most N-terminal non-
hydrophobic region orientates it within the cytoplasm or en-
doplasmic reticulum (ER) lumen, respectively [22]. Interest-
ingly, unlike the prokaryotic system, they found that charged
residues on subsequent non-hydrophobic regions have less of
a cytoplasmic in£uence on orientation, with highly charged
loops capable of being translocated into the ER lumen. A
recent review of structure and function of known Na-depen-
dent EAA transporters predicts that the N-terminal of
GLAST-1, which has ¢ve arginyl and eight lysyl residues,
would be cytoplasmic [20]. We therefore predict that the
N-terminal of GLAST-1a translated product would also be
cytoplasmic as it is composed of the same amino acid se-
quence. Since subsequent non-hydrophobic regions have less
of an orientational in£uence in eukaryotes, the loss of exon 3,
converting three hydrophobic regions into two, could £ip the
remaining C-terminal of the protein from intra- to extracellu-
lar (Fig. 4B). If this were the case then the second large extra-
cellular domain of GLAST-1, that is glycosylated at aspara-
gines 206 and 216 [12], would become cytoplasmic and
therefore not presented for glycosylation within the ER lu-
men. Assuming no further post-translational modi¢cation,
the unglycosylated GLAST-1a would have a molecular weight
of 54.4 kDa. We believe that the V55 kDa immunoreactive
protein expressed in brain (Fig. 3) represents unglycosylated
GLAST-1a, supporting our reversed orientation theory. Our
proposed model for the reversed orientation of the GLAST-1a
molecule, C-terminal of TM domain 1, presents us with the
interesting possibility that the orientation of the predicted
pore structure [2] and possibly the direction of glutamate
transport may also be reversed (Fig. 4). Whole cell clamping
experiments have shown that under appropriate conditions
glutamate transporters will operate in reverse, transporting
glutamate from inside to outside of the cell [23]. This has
recently been demonstrated in brain slices, where neurotoxic
release of glutamate due to anoxia was found to be largely
due to reversed operation of glutamate transporters [24].
While membrane transporters can transport in both directions
under appropriate ionic gradients [25], the novel splice variant
described in this paper encodes an ideal candidate protein for
an alternative mechanism of glutamate release that may in£u-
ence neurotoxic accumulation of glutamate.
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